Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis.

The aim of this study was to compare the in vitro activity of delafloxacin with other fluoroquinolones against bacterial pathogens recovered from inpatients with osteomyelitis, Acute Bacterial Skin and Skin-Structure Infections (ABSSSI). In total, 100 bacterial isolates (58 % Gram-negative and 42 % Gram-positive) recovered from inpatients between January and April 2021, were reidentified at species level by MALDI-TOF MS. Antimicrobial susceptibility testing was conducted using the broth microdilution method and the detection of biofilm formation was assessed through the microtiter plate assay. The screening for mecA was carried out by PCR, while mutations in the Quinolone Resistance Determining Regions (QRDR), specifically gyrA and parC, were analyzed using PCR followed by Sanger sequencing. Results showed that delafloxacin exhibited greater in vitro potency (at least 64-times) than the other tested fluoroquinolones (levofloxacin and ciprofloxacin) when evaluating Staphylococcus aureus (MIC50 ≤0.008 mg/L) and coagulase-negative Staphylococcus (MIC50 0.06 mg/L). Furthermore, delafloxacin (MIC50 0.25 mg/L) was at least 4 times more potent than other tested fluoroquinolones (MIC50 1 mg/L) against P. aeruginosa. No difference in delafloxacin activity (MIC50 0.03 mg/L) was observed against Enterobacter cloacae when compared with ciprofloxacin (MIC50 0.03 mg/L). Despite presenting low activity against K. pneumoniae isolates (22.2 %), delafloxacin exhibited twice the activity compared to both levofloxacin and ciprofloxacin. Delafloxacin also exhibited a strong activity (71.4 %‒85.7 %.) against biofilm producing bacterial pathogens tested in this study. Interestingly, 82.14 % of the staphylococci tested in this study harbored mecA gene. In addition, the gyrA and parC genes in fluoroquinolone-resistant Gram-negative isolates displayed different mutations (substitutions and deletions). Herein, we showed that delafloxacin was the most active fluoroquinolone against staphylococci (including MRSA) and P. aeruginosa when compared to other fluoroquinolones such as ciprofloxacin and levofloxacin.

Comparação entre determinações de glicemia capilar e venosa com glicosímetros e dosagem laboratorial da glicose plasmática venosa / Comparison of capilar and venous blood glucose using glucometers with laboratory determinations of venous plasma glucose

INTRODUÇÃO: O diabetes mellitus é uma doença crônica, das mais frequentes causas de morbimortalidade na população geral, sendo extremamente importante que seja feito o controle dos níveis da glicemia e o automonitoramento como fatores fundamentais para acompanhar o seu tratamento e prevenir as suas complicações. OBJETIVOS: Este estudo comparou valores de glicose determinados por diferentes metodologias, em amostras de sangue venoso e capilar de 76 pacientes atendidos no Centro de Atenção à Saúde do Hospital Universitário da Universidade Federal de Juiz de Fora. MÉTODOS: As glicemias capilar e venosa foram dosadas utilizando os glicosímetros Accu-Chek Performa (Roche) e Optium Xceed (Abott) e comparadas entre si e com a glicemia plasmática venosa determinada por automação laboratorial, considerada o método padrão do estudo. RESULTADOS: A análise dos dados obtidos revelou que, embora houvesse alta correlação (r≥0,95) entre as dosagens realizadas nos glicosímetros e o método padrão (GPAD), somente as médias obtidas para glicemia venosa com Accu-Chek Performa (GVenAC) e glicemia capilar com Optium Xceed (GCapOX) eram semelhantes entre si (p>0,05) e ao GPAD, enquanto as médias para glicemia capilar com Accu-Chek Performa (GcapAC) e glicemia venosa com Optium Xceed (GVenOX) se mostraram diferentes das demais (p<0,0001). CONCLUSÕES: Com base nos resultados obtidos, foi possível observar que o glicosímetro Accu-Chek Performa obteve os melhores resultados ao usar amostra de sangue venoso, enquanto o Optium Xceed obteve melhor desempenho com amostras de sangue capilar, o que significa que o desempenho dos dispositivos demonstrou ser dependente da amostra. (AU)